RWJBarnabas Health hematology fellow Matthew Karr, DO, describes his career path and outlines research interests in diseases such as CLL and CNS lymphoma. Karr focuses on novel triplet therapies, time-limited or continuous treatment options, in vivo CAR T cells, p53 reactivation, and bispecific antibodies for CNS lymphoma. He also explores how to evaluate AI-generated answers related to leukemia.
Source:CancerNetwork · Read Original
Leave a Reply